Bicuculline-sensitive primary afferent depolarization remains after greatly restricting synaptic transmission in the mammalian spinal cord.
Primary afferent neurotransmission is the fundamental first step in the central processing of sensory stimuli. A major mechanism producing afferent presynaptic inhibition is via a channel-mediated depolarization of their intraspinal terminals which can be recorded extracellularly as a dorsal root potential (DRP). Based on measures of DRP latency it has been inferred that this primary afferent depolarization (PAD) of low-threshold afferents is mediated by minimally trisynaptic pathways with GABAergic interneurons forming last-order axoaxonic synapses onto afferent terminals. We used an in vitro rat spinal cord preparation under conditions that restrict synaptic transmission to test whether more direct low-threshold pathways can produce PAD. Mephenesin or high divalent cation solutions were used to limit oligosynaptic transmission. Recordings of synaptic currents in dorsal horn neurons and population synaptic potentials in ventral roots provided evidence that conventional transmission was chiefly restricted to monosynaptic actions. Under these conditions, DRP amplitude was largely unchanged but with faster time to peak and reduced duration. Similar results were obtained following stimulation of peripheral nerves. Even following near complete block of transmission with high Mg(2+)/low Ca(2+)-containing solution, the evoked DRP was reduced but not blocked. In comparison, in nominally Ca(2+)-free or EGTA-containing solution, the DRP was completely blocked confirming that Ca(2+) entry mediated synaptic transmission is required for DRP genesis. Overall these results demonstrate that PAD of low-threshold primary afferents can occur by more direct synaptic mechanisms, including the possibility of direct negative-feedback or nonspiking dendroaxonic pathways.
Shreckengost
Jacob
J
Department of Physiology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
Calvo
Jorge
J
Quevedo
Jorge
J
Hochman
Shawn
S
D000818:Animals; D001640:Bicuculline / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism; D005071:Evoked Potentials / Q000187:drug effects; D018756:GABA Antagonists / Q000494:pharmacology*; D058787:GABA-A Receptor Antagonists; D066298:In Vitro Techniques; D008159:Lumbar Vertebrae; D008564:Membrane Potentials / Q000187:drug effects* / Q000502:physiology; D009475:Neurons, Afferent / Q000187:drug effects* / Q000502:physiology; D010525:Peripheral Nerves / Q000502:physiology; D020671:Posterior Horn Cells / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000378:metabolism; D026941:Sodium Channel Blockers / Q000494:pharmacology; D013116:Spinal Cord / Q000187:drug effects* / Q000502:physiology; D013569:Synapses / Q000187:drug effects / Q000502:physiology; D009435:Synaptic Transmission / Q000187:drug effects* / Q000502:physiology; D013779:Tetrodotoxin / Q000494:pharmacology; D013997:Time Factors
D018756:GABA Antagonists; D058787:GABA-A Receptor Antagonists; D011963:Receptors, GABA-A; D026941:Sodium Channel Blockers; D013779:Tetrodotoxin; D002118:Calcium; D001640:Bicuculline
Eur J Neurosci. 1996 Dec;8(12):2492-8
8996798
Exp Brain Res. 2002 Aug;145(4):448-56
12172656
J Neurosci. 2004 Mar 17;24(11):2774-81
15028770
J Neurophysiol. 1987 May;57(5):1288-313
3585469
Neuropharmacology. 1989 Feb;28(2):161-73
2716970
J Neurophysiol. 1981 Sep;46(3):506-16
7299431
J Comp Neurol. 2008 Aug 1;509(4):436-48
18521856
J Comp Neurol. 1992 Jul 1;321(1):65-82
1613140
Neuropharmacology. 1979 Aug-Sep;18(8-9):647-53
492485
J Physiol. 1986 Jan;370:515-30
2870179
Neuroscience. 2002;115(1):1-5
12401316
Neurosci Lett. 1992 Dec 14;148(1-2):19-22
1363754
J Physiol. 2000 Oct 1;528 Pt 1:115-22
11018110
J Neurophysiol. 2005 Oct;94(4):2867-77
16033939
J Neurosci Res. 2004 Jan 15;75(2):194-202
14705140
J Physiol. 1962 Jan;160(1):62-93
16992116
Mol Pharmacol. 1999 Feb;55(2):248-54
9927615
J Physiol. 2009 Jan 15;587(2):379-99
19047211
Brain Res. 1976 Nov 19;117(1):153-6
1086700
J Physiol. 1958 Jun 18;142(1):1-21
13564417
J Neurosci. 2006 May 31;26(22):5920-8
16738234
J Neurochem. 2007 Jun;101(6):1607-18
17542812
Int Rev Neurobiol. 1979;21:217-58
43844
J Physiol. 1958 Jul 14;142(2):360-5
13564442
Exp Brain Res. 1999 Nov;129(1):1-37
10550500
Br J Pharmacol. 2007 Feb;150 Suppl 1:S1-168
17279063